Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments

A Phase II, Single Arm Study Of CP-751,871 In Patients With Refractory Metastatic Adenocarcinoma Of The Colon Or Rectum

This study will test if there is any survival benefit in patients with refractory metastatic colorectal cancer that receive CP-751, 871.

Inclusion Criteria:

• Patients who have stage IV colorectal cancer
• Patients whose disease has worsened despite prior anti-cancer therapy
• Patients who have satisfactory bonemarrow, kidney and liver function

Exclusion Criteria:

• Patients who are being simultaneously treated with another anti-cancer therapy.
• Patients who have previously received anti-cancer therapy that works like CP-751, 871 (targets insulin-like growth factor receptor)
• Patients that are pregnant or breast-feeding